Marina Popova - Concepedia

Author

Marina Popova

First Pavlov State Medical University of St. Petersburg ORCID

Also Known As

Evgeniya S. Borzenkova, I. S. Moiseev, M O Popova, M Popova, M. O Popova, M. O. Popova, M. Popova, M. О. Popova, M., Popova, M.O. Popova

140

Publications

923

Citations

H-Index

Concepts

All Affiliations

First Pavlov State Medical University of St. Petersburg University Hospital Centre Zagreb Azienda Ospedaliera San Gerardo Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases Universitat Autònoma de Barcelona

About

Marina Popova is an author at First Pavlov State Medical University of St. Petersburg specializing in medicine, pharmacotherapy, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	107
2	Health Sciences	2	2	48
3	Public Health	2	2	178
4	Epidemiology	2	2	178
5	Head And Neck Surgery	1	1	14

Marina Popova

Publications

696

Citations

H-Index

Page 1

	Year	Citations
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) Livio Pagano, Jon Salmanton‐García, Francesco Marchesi, Journal of Hematology & Oncology	2021	312
Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study Sheena Mukkada, Nickhill Bhakta, Guillermo Chantada, The Lancet Oncology Global CharacteristicsPediatric EpidemiologySars-cov-2 InfectionCovid-19 PandemicPediatrics	2021	132
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) Francesco Marchesi, Jon Salmanton‐García, Ziad Emarah, Haematologica Hematological MalignancyLong CovidMedicineAcute Myeloid LeukemiaCovid-19 Pandemic	2022	46
Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia Marina Popova, L. S. Zuborovskaya, Ilya S. Zuzgin, Mycoses	2014	44
A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma Kirill V. Lepik, Liudmila Fedorova, Elena Kondakova, HemaSphere Surgical OncologyRelapsed/refractory Hodgkin LymphomaFixed DosePharmacotherapyMetronomic Chemotherapy	2020	34
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure Kirill V. Lepik, N.B. Mikhailova, Elena Kondakova, HemaSphere	2020	26
Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations Artem Gusak, Liudmila Fedorova, Kirill V. Lepik, Cancers	2021	25
Nivolumab in Primary CNS Lymphoma and Primary Testicular Lymphoma with CNS Involvement: Single Center Experience D.I. Shmidt, A. Yu. Polushin, Elena Kondakova, Blood	2020	22
MUCORMYCOSIS IN ONCOHEMATOLOGY PATIENTS (results of the prospective study) Yu. L. Avdeenko, Marina Popova, Inese Mihailova, Oncohematology	2017	15
Mucormycosis of the bones of the facial skull, nasal cavity and par anasal sinuses in patients with COVID19 A.I. Yaremenko, Sergei Karpischenko, Marina Popova, Clinical Microbiology and Antimicrobial Chemotherapy Diagnostic MycologyFungal DiseasesOtorhinolaryngologyOral MedicineFacial Skull	2021	14

Page 1